Efficacy and safety of immunomaintenance therapy after concurrent double or single drug chemotherapy for locally advanced esophageal squamous cell carcinoma: a phase II, single arm, multicenter study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048546

Enrollment

Unknown

Registered

2021-07-10

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Experimental group:Immune maintenance therapy for one year

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Esophageal squamous cell carcinoma confirmed by histology or cytology; 2. Aged 18 to 75 years; 3. ECOG score is 0-2 points; 4. Blood routine, liver function, kidney function, electrolytes, etc. meet the treatment standards; 5. Tumor stage II-III, no esophageal perforation, active esophageal bleeding or obvious tracheal or thoracic large vessel invasion; 6. The lower limit of primary esophageal lesions is less than 3 cm from the junction of esophagus and stomach; 7. No history of radiotherapy and chemotherapy for thoracic tumor; 8. The patients signed a formal informed consent for treatment and voluntarily participated in this experiment.

Exclusion criteria

Exclusion criteria: 1. Received immunotherapy in the past; 2. There are other malignant tumors; 3. Patients with severe autoimmune diseases such as immune myocarditis and immune pneumonia.

Design outcomes

Primary

Measure	Time frame
One year progression free survival rate;	—

Countries

China

Contacts

Public ContactXiang Miao

Mianyang Central Hospital

xiangmiao911@163.com+86 15881657390

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026